Phase III Study of Cyclophosphamide, Doxorubicin, and Fluorouracil (CAF) Plus Leucovorin Versus CAF for Metastatic Breast Cancer: Cancer and Leukemia Group B 9140
- 1 May 2003
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (9) , 1819-1824
- https://doi.org/10.1200/jco.2003.05.119
Abstract
Purpose: To determine whether biochemical modulation with LV (leucovorin) enhances the efficacy of CAF (cyclophosphamide, doxorubicin, and fluorouracil) against metastatic breast cancer.Keywords
This publication has 23 references indexed in Scilit:
- Combination of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer: an interim reportEuropean Journal Of Cancer, 2002
- A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinomaCancer, 2000
- Biomodulation of Fluorouracil in Colorectal CancerCancer Investigation, 1998
- Thymidylate synthase and drug resistanceEuropean Journal Of Cancer, 1995
- The impact of mammography on breast cancer detectionAnnals of Oncology, 1993
- 5-Fluorouracil Plus Leucovorin in Women with Metastatic Breast Cancer A Phase II StudyAmerican Journal of Clinical Oncology, 1991
- Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.Journal of Clinical Oncology, 1987
- 5-Fluorouracil and High-Dose Folinic Acid as Salvage Treatment of Advanced Breast Cancer: An UpdateOncology, 1987
- Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate binding to human thymidylate synthetaseBiochemical Pharmacology, 1981
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958